Achieve Life Sciences Inc. (ACHV)

1.811 +0.021 (+1.173%)

IEX Real-Time Price

9:58:40 AM EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.79

Price Open 1.79

Volume: 2,570

Avg Volume: 339,983

Market Cap: 12.17M

P/E Ratio -

52 Wk Range 1.7-32



ACHV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-06-15
2.76M
77,912
0.91
2.82%

2018-05-31
129,079
45,443
0.70
35.21%

2018-05-15
129,079
51,553
0.89
39.94%

2018-04-30
10.15M
556,139
12.50
5.48%




ACHV Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-01
Q4 2017
N/A
0.00 (0)
-0.32
0.00

2018-02-22
Q4 2017
N/A
0.00 (0)
-0.32
0.00

2017-02-23
Q4 2016
N/A
0.00 (0)
-0.32
0.00

News

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q3 2018 Results - Earnings Call Transcript (2018-11-07 22:49 SeekingAlpha)

Achieve Life Sciences, Inc. (ACHV) Q3 2018 Earnings Conference Call November 07, 2018, 04:30 PM ET Executives Jaime Welch - EVP, Commercial Richard Stewart - Chairman and CEO John Bencich - EVP, CFO and Operating Officer Cindy Jacobs - EVP and Chief Medical Officer Analysts …

 


Statistics

Shares Outstanding: 6.72M

Top 15 Institution Percent: 7.30

Price To Sales: N/A

Price To Book: 0.85

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -84.79

Return On Equity: -102.95

Profit Margin: N/A

Price History

Beta: 2.19

50-day Moving Avg: 2.41

200-day Moving Avg: 7.31

YTD Change: -87.57

5-day Change: -8.21

1-month Change: -26.34

3-month Change: -41.12

6-month Change: -84.83

1-year Change: -87.30

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Achieve Life Sciences Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.achievelifesciences.com

Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next generation cancer therapeutics.